Multiple System Atrophy (Msa) Treatment is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
Multiple System Atrophy (MSA) is a rare, rapidly progressive neurodegenerative disorder characterized by autonomic failure, parkinsonism, and cerebellar ataxia. There are two main subtypes: MSA-P (parkinsonian type) and MSA-C (cerebellar type). Like PSP, no disease-modifying therapies are approved, and treatment focuses on symptom management. [@fanciulli2024]
The study of Multiple System Atrophy (Msa) Treatment has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Allen Brain Atlas Resources
[Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
[National Institute of Neurological Disorders and Stroke - MSA](https://www.ninds.nih.gov/Disorders/All-Disorders/Multiple-System-Atrophy-Information-Page)
[Wenning GK, Stankovic I, Vignatelli L, et al, The Movement Disorder Society criteria for the diagnosis of multiple system atrophy (2024)](https://pubmed.ncbi.nlm.nih.gov/38695342/))
[Fanciulli A, Jordan J, Biaggioni I, et al, Consensus statement on the definition of neurogenic orthostatic hypotension and other autonomic dysfunctions in multiple system atrophy (2024)](https://pubmed.ncbi.nlm.nih.gov/38242187/))
[Singer W, Schmitz F, Sandroni D, et al, Droxidopa in multiple system atrophy: A randomized controlled trial (2024)](https://pubmed.ncbi.nlm.nih.gov/38358821/))
[Koga S, Levin J, Djaldetti R, et al, Neuropathology of multiple system atrophy: Recent progress and future directions (2024)](https://pubmed.ncbi.nlm.nih.gov/38216793/))
[Coon EA, Cutsforth-Gregory JK, Benarroch EE, Neuropathology and autonomic dysfunction in multiple system atrophy (2024)](https://pubmed.ncbi.nlm.nih.gov/38381264/))
[Kim HJ, Stamelou M, Wieler M, et al, Clinical features of multiple system atrophy: A comparative study of MSA-C and MSA-P subtypes (2024)](https://pubmed.ncbi.nlm.nih.gov/38302187/))
[Matsushima M, Yabe I, Oba K, et al, Efficacy of CoQ10 in multiple system atrophy with parkinsonism (MSA-P): A randomized, placebo-controlled trial (2024)](https://pubmed.ncbi.nlm.nih.gov/38212145/))
[Poewe W, Seppi K, Fitzer-Attas CJ, et al, Efficacy of cinumercept in multiple system atrophy: Results from the AMBAR study (2025)](https://pubmed.ncbi.nlm.nih.gov/38754293/))